Newsbenzinga
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
· Published
Article summary
Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.
An excerpt from the original article.
Comments —
Loading comments…